Kananathan Ratnavelu

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 249 citations

Oncology, Met Amplification, Medicine +10

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 55 citations

Antifibrotic Therapy, Fortis-m Trial, Medicine +9

Effect of time delay on survival in patients with non-small cell lung cancer — A Malaysian study

L-C. Loh, LY Chan, Selvaratnam Govindaraju et al. · Asia Pacific Journal of Public Health · 2006 · 14 citations

Advanced Lung Disease, Cancer Management, Prognosis +16

Identification of a functional variant in <i>SPLUNC1</i> associated with nasopharyngeal carcinoma susceptibility among Malaysian Chinese

Poh‐Yin Yew, Taisei Mushiroda, Kazuma Kiyotani et al. · Molecular Carcinogenesis · 2011 · 12 citations

Autologous immune enhancement therapy against an advanced epithelioid sarcoma: A case report

Kananathan Ratnavelu, Baskar Subramani, Chithra Ramanathan Pullai et al. · Oncology Letters · 2013 · 12 citations · Full text